Brain
- GIOVANNONI G, James L, Adeniran AA, Gold J, et al
The case for targeting latent and lytic Epstein-Barr virus infection in multiple
sclerosis.
Brain. 2025 May 6:awaf170. doi: 10.1093.
J Neuroimmunol
- PETROU P, Kassis I, Levi Y, Yaghmour N, et al
Kinetics of serum NFL and GFAP and changes in cognitive functions, in MS patients
treated with repeated administrations of autologous mesenchymal stem cells
(MSC-NG01).
J Neuroimmunol. 2025;403:578613.
J Neurol
- FREEDMAN DE, Oh J, Einstein G, Feinstein A, et al
Aging and the neuropsychiatry of multiple sclerosis: a cross-sectional study.
J Neurol. 2025;272:375.
- KOLB H, Shachaf Y, Fainberg K, Golan M, et al
Intrathecal methotrexate in progressive multiple sclerosis: a phase 1 open-label
study with long-term follow-up.
J Neurol. 2025;272:374.
- HERMAN D, Tanniou J, Leray E, Pierret C, et al
Analyzing recurrent events in multiple sclerosis: a review of statistical models
with application to the MSOAC database.
J Neurol. 2025;272:371.
Mayo Clin Proc
- KWON S, Han KD, Jung JH, Cho EB, et al
Risk of Autoimmune Rheumatic Diseases in Multiple Sclerosis and Neuromyelitis
Optica Spectrum Disorder: A Nationwide Cohort Study in South Korea.
Mayo Clin Proc. 2025;100:801-813.
- TORKILDSEN O
Multiple Sclerosis, NMOSD, and the Risk of Autoimmune Diseases.
Mayo Clin Proc. 2025;100:773-775.
Mult Scler
- MACCARRONE D, Prados F, Ciccarelli O
The relationship between cladribine and reduced regional grey matter volume loss
in people with relapsing-remitting multiple sclerosis.
Mult Scler. 2025 May 3:13524585251338772. doi: 10.1177/13524585251338772.
- LOREFICE L, Zivadinov R
Treating comorbidities in multiple sclerosis is disease-modifying: Yes.
Mult Scler. 2025 May 3:13524585251338750. doi: 10.1177/13524585251338750.
PLoS Biol
- HILL BM, Holloway RK, Forbes LH, Davies CL, et al
Monocyte-secreted Wnt reduces the efficiency of central nervous system
remyelination.
PLoS Biol. 2025;23:e3003073.
Free Medical Abstracts
Privacy Policy
Sponsors
Share
© Amedeo 1997-2016